Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (December 2017)
36 slides from Noxopharm's investor presentation, Dec 6, 2017
Slide 1: Open Briefing 6 December 2017
Open Briefing 6 December 2017 1
Slide 2: Oncology
ONCOLOGY 2
Slide 3: NOX66 Idronoxil (lipophilic form)
Noxopharm NOX66 Idronoxil (lipophilic form) 3
Slide 4: About Idronoxil: multiple anti-cancer actions
Noxopharm ABOUT IDRONOXIL Multiple anti-cancer actions 1. Inhibits DNA repair (inhibits PARP-1, topoisomerases 1 and 2) 2. Promotes anti-tumour immunity (Increases NK (natural killer) cell activity) 4
Slide 5: Oral Idronoxil NOX66
Noxopharm Oral Idronoxil NOX66 LIPROSE Technology Excreted Excreted quickly slowly (45 min) (10 hours) Does NOT Crosses BBB cross BBB 5
Slide 6: DARRT
Noxopharm DARRT Direct and Abscopal Response to Radio-Therapy 6
Slide 7: Limitation of radiotherapy
Limitation of radiotherapy Noxopharm Metastatic cancer too extensive for radiation 7
Slide 8: Direct Response to Radio-Therapy
DIRECT Response to Radio-Therapy Noxopharm Radiotherapy applied to large Shrinkage of irradiated Direct radio-sensitising effect tumours tumours for pain relief 8
Slide 9: Direct Response to Radio-Therapy
DIRECT Response to Radio-Therapy Noxopharm NOX66 Radiotherapy applied to large Shrinkage of irradiated Seeking complete remission of Direct radio-sensitising effect Direct radio-sensitising irradiated tumours effect tumours for pain relief tumours 9
Slide 10: Abscopal Response to Radio-Therapy
ABSCOPAL Response to Radio-Therapy Noxopharm Exposed tumours respond ✙ Non-exposed tumours also respond Low-dose radiotherapy Seeking Direct complete remission radio-sensitising effectof Abscopal response irradiated tumours 10
Slide 11: Features of an abscopal response
Noxopharm Features of an abscopal response Rare – very rare phenomenon Complete – primary AND secondary tumours respond Durable – potentially permanent Unrestricted – range of cancers reportedly involved Short treatment – single course of treatment (7-14 days) Low toxicity – low-grade radiation sick
Slide 12: DARRT
DARRT Noxopharm Direct Effect Abscopal Effect Ø Patients with multiple (>3) tumours Ø Irradiate 1-2 tumours (5 days) External Beam RT Ø NOX66 14 days Ø Scan + 2 months and 4 months 12
Slide 13: DARRT
DARRT Noxopharm Direct Effect Abscopal Effect Ø Prostate cancer (metastatic castrate-resistant) Ø Solid common cancers (eg. lung, breast, melanoma) External Beam RT Ø Rare cancers (eg. sarcomas) 13
Slide 14: DARRT
DARRT Noxopharm Direct Effect Abscopal Effect Ø 177 Lutetium-PSMA-617 Ø 4 x monthly intravenous injections of LuPSMA/10 Brachytherapy days NOX66 Ø Prostate cancer (metastatic castrate-resistant) 14
Slide 15: DARRT: NOX66-001 Phase 1b Study
DARRT Noxopharm Where NOX66 + Radiotherapy needs a boost ……… NOX66-001 Phase 1b Study Georgia + Low-dose carboplatin (AUC4 – monthly) 400 mg NOX66 5 patients: 1 progressive; 4 non-progressive 800 mg NOX66 7 patients: 1 progressive; 5 non-progressive; 1 partial response 15
Slide 16: What will a 'good response' look like?
Noxopharm What will a ‘good response’ look like ? • Lung Cancer trial (582 patients evaluated) • Opdivo vs standard chemotherapy • Survival of 50% of patients - 12.2 months v 9.4 months • Time to disease progression – 2.3 months v 4.2 months • Overall Response Rate – 19% v 12% • Four Complete Respon
Slide 17: Moving towards first registration
Noxopharm Moving towards first registration Notes: Target Indication: NOX66 in combination with Radiotherapy for the • Different Global Regulators treatment of patients with metastatic cancer may modify indication for specific tumour types Studies: • Indication may also list NOX66-002A: Determine Do
Slide 18: Beyond the trials to reach registration
Noxopharm Beyond the trials to reach registration • Manufacturing and formulation: Optimise NOX66 formulation; GMP Manufacturing • Pre-clinical / non-clinical: in vitro and animal studies to meet regulatory and other requirements for registration and marketing NEW!! • Medical Affairs: Liaison with o
Slide 19: Communicating Trials Progress 2018
Noxopharm Communicating Trials Progress 2018 • Progress – based on Data Safety Monitoring Committee Review • Independent body – researchers and statisticians • Regular meetings during trials – expect ~6 across trials in 2018 • Review overall progress à decisions on continuation • Findings of DSMBs w
Slide 20: 20
20
Slide 21: 2 technologies 3 drugs 3 indications
2 technologies 3 drugs 3 indications NYX-104 v Stroke v Concussion LIPROSE v Severe epilepsy NYX-205 Peripheral neuropathy Nyx-104 P-PDT NYX-330 Hypercholesterolaemia 21
Slide 22: NYX-104
NYX-104 Inhibitor of excitotoxicity head stroke trauma Excitotoxicity epilepsy concussion 22
Slide 23: NYX-104
NYX-104 Receptors activated by small amount of Small amount of glutamate. Ca++ allowed to enter neuron, activating a series of events that leads to generation of an electrical signal. 23
Slide 24: NYX-104: Excitotoxicity
NYX-104 Excitotoxicity Size of original area of Days to weeks later, damage from stroke excitotoxicity has increased area or concussion of damage up to 10-times 24
Slide 25: NYX-104
NYX-104 1. University of NSW Translational Neuroscience Facility: Breakthrough identification of key protein promoting excitotoxicity (TrpC3 isotope) 2. In vitro screen of NOX compounds: NYX-104 inhibits TrpC3 3. Mouse model of human stroke: NYX-104 is potent inhibitor of excitotoxicity. 70% reducti
Slide 26: NYX-205
NYX-205 Anti-inflammatory Designed to cross the blood-nerve barrier Diabetes Chemotherapy Peripheral neuropathy Alcoholism Shingles 26
Slide 27: NYX-205 Peripheral neuropathy
NYX-205 Peripheral neuropathy Incidence in US estimated at 20 million: Blood-nerve barrier is major obstacle to • Diabetes effective treatment. NYX-205 designed to cross • Alcohol abuse this barrier. • Chemotherapy 27
Slide 28: NYX-205: Targeting peripheral neuropathy in cancer patients
NYX-205 Peripheral neuropathy Targeting peripheral neuropathy in cancer patients receiving chemotherapy 60% incidence at 3 months 30% incidence at 6 months Currently no effective treatment 28 NIH
Slide 29: NYX-330 Hypercholesterolemia
NYX-330 Hypercholesterolemia Heart Stroke disease High blood LDL Hypertension Alzheimer’s 29
Slide 30: NYX-330 Hypercholesterolemia
NYX-330 Hypercholesterolemia • PCSK9 identified as superior drug target compared to statin drugs for lowering blood LDL levels. • PCSK9 is plasma protein that binds to the LDL-LDL receptor complex, preventing recycling of the LDL receptor and thereby increasing LDL levels. PCSK9 declared an unsuitab
Slide 31: NYX-330
NYX-330 Hypercholesterolemia Suitable binding site identified on PCSK9 for attachment of small molecule. NYX-330 blocks binding of PCSK9 to LDL- LDL receptor complex. 31
Slide 32: Nyrada: US-registered, non-oncology small molecules
Ø US-registered Ø Focus on small molecules, non-oncology Ø 67% owned by NOX; 33% Altnia Holdings Ø Currently public unlisted; proposed US listing in 12-18 months 32
Slide 33: Offer: Raise A$6,000,000 seed capital
OFFER: Ø Raise = AUD$6,000,000 Ø Seed capital = 1,500,000 New Shares (A$4 each; 2 Options per 3 Shares) Ø Capital structure post-exercise of Options • NOX 50% • Altnia 25% • Seed investors 25% Application for Shares by sophisticated investors, non-US residents only. Information Memorandum available:
Slide 34: Disclaimer
Disclaimer • This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to subscrib
Slide 35: www.nyrada.com
www.nyrada.com 35
Slide 36: Contact
i . ——— —_ NOXOPHARM [ii